Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.

@article{Mongan2015OutcomesIG,
  title={Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.},
  author={A M Mongan and Roshni Kalachand and Sara King and Naoimh J O'Farrell and Dermot Power and Narayanasamy Ravi and Cian B. Muldoon and Ken O'Byrne and John Vincent Reynolds},
  journal={Irish journal of medical science},
  year={2015},
  volume={184 2},
  pages={417-23}
}
BACKGROUND The MAGIC/UK Medical Research Council (MRC) trial set the standard of care for treatment of resectable gastric and junctional adenocarcinoma, demonstrating that perioperative chemotherapy with epirubicin, cisplatin and 5-fluorouracil (ECF) confers a survival benefit over surgery alone. The randomized ECF for advanced and locally advanced esophagogastric cancer (REAL-2) trial showed that, in the metastatic setting, the EOX regimen (epirubicin, oxaliplatin and capecitabine) is as… CONTINUE READING